Molecular biology and novel therapeutics for IDH mutant gliomas: The new era of IDH inhibitors
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2024
DOI: 10.1016/j.bbcan.2024.189102 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2024. Verfasst von Yosuke Kitagawa und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, 02114 Boston, MA, USA; Translational Neuro-Oncology Laboratory, M…. Hauptthemen laut MEDLINE: Isocitrate Dehydrogenase, Glioma, Mutation, Brain Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 174 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science, Uehara Memorial Foundation, Nakatani Foundation for Advancement of Measuring Technologies in Biomedical Engineering.
Abstract (Originalsprache)
Gliomas with Isocitrate dehydrogenase (IDH) mutation represent a discrete category of primary brain tumors with distinct and unique characteristics, behaviors, and clinical disease outcomes. IDH mutations lead to aberrant high-level production of the oncometabolite D-2-hydroxyglutarate (D-2HG), which act as a competitive inhibitor of enzymes regulating epigenetics, signaling pathways, metabolism, and various other processes. This review summarizes the significance of IDH mutations, resulting upregulation of D-2HG and the associated molecular pathways in gliomagenesis. With the recent finding of clinically effective IDH inhibitors in these gliomas, this article offers a comprehensive overview of the new era of innovative therapeutic approaches based on mechanistic rationales, encompassing both completed and ongoing clinical trials targeting gliomas with IDH mutations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, 02114 Boston, MA, USA; Translational Neuro-Oncology Laboratory, Massachusetts General Hospital, Harvard Medical School, 02114 Boston, M…
- Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, 02115 Boston, MA, USA.
- Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 7008558, Okayama, Japan.
Förderung
- Japan Society for the Promotion of Science
- Uehara Memorial Foundation
- Nakatani Foundation for Advancement of Measuring Technologies in Biomedical Engineering
Zitieren
APA
Kitagawa, Y., Kobayashi, A., Cahill, D. P., Wakimoto, H., & Tanaka, S. (2024). Molecular biology and novel therapeutics for IDH mutant gliomas: The new era of IDH inhibitors. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. https://doi.org/10.1016/j.bbcan.2024.189102
Vancouver
Kitagawa Y, Kobayashi A, Cahill DP, Wakimoto H, Tanaka S. Molecular biology and novel therapeutics for IDH mutant gliomas: The new era of IDH inhibitors. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2024. doi:10.1016/j.bbcan.2024.189102
BibTeX
@article{Kitagawa2024,
author = {Kitagawa, Yosuke and Kobayashi, Ami and Cahill, Daniel P and Wakimoto, Hiroaki and Tanaka, Shota},
title = {Molecular biology and novel therapeutics for IDH mutant gliomas: The new era of IDH inhibitors},
journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
year = {2024},
doi = {10.1016/j.bbcan.2024.189102}
}
EUVIMED